ME/CFS (Human)(6 expert discussions analyzed)

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is a complex multi-system illness whose leading clinical feature is post-exertional malaise (PEM) — a worsening of all symptoms hours to days after physical or cognitive exertion. ME/CFS frequently arises after viral infections, with Epstein-Barr virus (EBV / mononucleosis) historically the most studied trigger and COVID-19 now driving a substantial new patient population. No definitive biomarker exists; diagnosis uses symptom-criteria catalogues such as the Canadian Consensus Criteria, the Institute of Medicine (IOM) criteria, or the International Consensus Criteria for ME. The disease has long been under-recognized in clinical care, often dismissed as functional or psychosomatic — a framing the modern research consensus rejects on biological grounds.

Current ME/CFS research points to multiple biological mechanisms operating across different patient subtypes. A subset of patients (Scheibenbogen, Charité Berlin) show elevated autoantibodies against beta-2 adrenergic receptors that may drive autonomic and circulatory symptoms. Other patients show patterns of persistent inflammation, mitochondrial dysfunction, or immune exhaustion. The autoantibody-driven subtype is the focus of intense current research because it suggests treatments may target the underlying immune disturbance rather than just managing symptoms one at a time. Early Charité research showed that immunoadsorption (a temporary clearing of antibodies from the blood) improved symptoms in about 75 percent of autoantibody-positive patients — a bridge therapy that points toward more lasting interventions.

A German medical commission has proposed five existing drugs for off-label reimbursement for ME/CFS and Long COVID: Low-Dose Naltrexone (LDN) at 1.5 to 4.5 mg (which acts through anti-inflammatory mechanisms at low dose, distinct from its opioid-blocking action at the standard 50 mg dose), Metformin (started within 7 days of COVID infection for prevention, with the strongest effect within 3 days per the Bramante 2023 trial — about a two-thirds risk reduction), Agomelatine (sleep and circadian rhythm support), Vortioxetine (depression with cognitive-symptom benefit), and Ivabradine (heart rate management for autonomic symptoms). Note that metformin currently has stronger evidence for reducing Long COVID risk when started early during acute COVID than for treating established ME/CFS; the prevention-vs-treatment distinction matters when discussing metformin with a clinician. If the German Federal Joint Committee (G-BA) approves the broader list, doctors could prescribe these drugs without the legal and financial risk that off-label use currently carries. Patient-survey data from the broader Long COVID research literature also rank LDN, antihistamines, and compression stockings as highly helpful, though large randomized trials are still scarce.

Three B-cell or plasma-cell depletion trials at the Charité are being designed in parallel rather than sequentially: targeting CD19, CD20, and CD38 cell-surface markers. The hypothesis is that removing the antibody-producing immune cells themselves may produce lasting recovery for autoantibody-positive ME/CFS patients, rather than the temporary effect of immunoadsorption. Results are pending. The approach connects ME/CFS to other autoantibody-mediated conditions and raises the prospect that bioelectronic medicine, antiviral approaches, and immune-modulating therapies may eventually converge into combination protocols matched to specific subtypes — the same framing that has emerged in Long COVID research.

Across all subtypes and research directions, pacing remains the most reliable practical principle: doing just enough each day to avoid the delayed energy crash that defines post-exertional malaise. Standard cardio rehabilitation that pushes through fatigue typically worsens ME/CFS, sometimes dramatically. Specialist clinics (including university-affiliated post-viral illness clinics) understand this and adapt rehabilitation accordingly. Mainstream primary care often lags behind research consensus and may still recommend graded exercise therapy or generic rehabilitation that the modern ME/CFS literature has explicitly retracted as harmful in most cases. Knowing which type of clinical setting you are in is itself a practical decision lever for patients and family members. If a reader takes only one practical lesson from this page, it should be this: avoid triggering post-exertional malaise through pacing. The conversations about Low-Dose Naltrexone, autoantibody testing, B-cell depletion trials, and early metformin all sit on top of that foundation; pacing is what protects you while the rest of the picture clarifies.